Close to 120 companies across the globe claim to possess the required

Development initiatives of HPAPIs and cytotoxic drugs are generally very demanding, both in terms of experience and capital investment. Most companies generally lack the necessary resources to meet the aforementioned requirements and are unable to set up dedicated HPAPI and cytotoxic drug manufacturing facilities. This has led to an increased demand for contract manufacturing service providers in this field.

 

To order this 300+ page report, which features 75+ figures and 150+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html

 

The USD 25 billion (by 2030) financial opportunity within the HPAPI and cytotoxic drugs contract manufacturing market has been analyzed across the following segments:

Type of Product

HPAPIs

Highly Potent Finished Dosage Forms

Company SizeSmall-sizedMid-sizedLarge / Very Large

Scale of Operation

Preclinical / ClinicalCommercial

Type of Pharmacological Molecule

Small MoleculesBiologics

Type of Highly Potent Finished Dosage Form

Injectables

Oral Solids

Creams

Others

Key geographical regions

North America

Europe

Asia Pacific

Rest of the World

The “HPAPI and Cytotoxic Drugs Manufacturing (3rd Edition) 2020-2030.”report features the following companies, which we identified to be key players in this domain: 

AbbVie Contract ManufacturingCARBOGEN AMCISCatalentEvonikFormosa LaboratoriesIntasLonzaMabPlexPfizer CentreOne

 

Table of Contents

 

1. Preface

2. Executive Summary

3. Introduction

4. Market Landscape

5. Company Competitive Analysis

6. HPAPI and Cytotoxic Drugs Contract Manufacturers based in North America: Company Profiles

7. HPAPI and Cytotoxic Drugs Contract Manufacturers based in Europe: Company Profiles

8. HPAPI and Cytotoxic Drugs Contract Manufacturers based in Asia Pacific: Company Profiles

9. Partnerships and Collaborations

10. Recent Expansions

11. Capacity Analysis

12. Market Sizing and Opportunity Analysis

13. Case-In-Point: Contract Manufacturing of Antibody Drug Conjugates

14. Concluding Remarks

15. Executive Insights

16. Appendix 1: Tabulated Data

17. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html  

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]